Buy HUMA by May 28, 2025.

Humacyte ($HUMA) just announced the commercial launch of Symvess, which was fully FDA approved in December 2024 for use in vascular trauma. They also announced the patent for their manufacturing tech. Check out their press releases, product portfolio, and impressive sales team below. Gearing up for an incredible 2025 and beyond! FDA approval: [https://humacyte.gcs-web.com/news-releases/news-release-details/humacyte-announces-fda-approval-symvesstm-acellular-tissue](https://humacyte.gcs-web.com/news-releases/news-release-details/humacyte-announces-fda-approval-symvesstm-acellular-tissue) Commercial launch: [https://humacyte.gcs-web.com/news-releases/news-release-details/humacyte-announces-commercial-launch-symvesstm-acellular-tissue](https://humacyte.gcs-web.com/news-releases/news-release-details/humacyte-announces-commercial-launch-symvesstm-acellular-tissue) Manufacturing patent: [https://humacyte.gcs-web.com/news-releases/news-release-details/humacyte-announces-issuance-us-patent-covering-manufacturing](https://humacyte.gcs-web.com/news-releases/news-release-details/humacyte-announces-issuance-us-patent-covering-manufacturing) Portfolio / Corporate Presentation: [https://humacyte.gcs-web.com/static-files/21baccf8-03ed-4534-95d1-fdf84241f9a1](https://humacyte.gcs-web.com/static-files/21baccf8-03ed-4534-95d1-fdf84241f9a1) LinkedIn Sales Team profiles: [https://www.linkedin.com/posts/morgan-rankin-61a5bb14\_biotech-innovation-humacyte-activity-7295917968121614337-K-qu/?utm\_source=share&utm\_medium=member\_desktop&rcm=ACoAADPfyf0BK14glulYascd3nexLYe614co6hg](https://www.linkedin.com/posts/morgan-rankin-61a5bb14_biotech-innovation-humacyte-activity-7295917968121614337-K-qu/?utm_source=share&utm_medium=member_desktop&rcm=ACoAADPfyf0BK14glulYascd3nexLYe614co6hg) I hold just over 6000 shares around $5.50.